cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Monte Rosa Therapeutics Inc
1 watching
Current Price
$7.71
$0.07
(0.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
372.95M
52-Week High
52-Week High
15.54
52-Week Low
52-Week Low
6.05
Average Volume
Average Volume
0.11M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization372.95M
icon52-Week High15.54
icon52-Week Low6.05
iconAverage Volume0.11M
iconDividend Yield--
iconP/E Ratio--
What does the Monte Rosa Therapeutics Inc do?
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Read More
How much money does Monte Rosa Therapeutics Inc make?
News & Events about Monte Rosa Therapeutics Inc.
Globe Newswire
5days ago
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the ...
Globe Newswire
30days ago
MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expressionDisclosure of initial data from Phase 1 arm of ongoing Phase 1/2 clinical trial evaluating MRT-2359 expected in ...
Globe Newswire
1month ago
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan ...
Globe Newswire
10 months ago
Data Highlight Essential Role of GSPT1 in Sustaining Myc-induced Translational Addiction in Solid Tumors BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced ...
Frequently Asked Questions
Frequently Asked Questions
What is Monte Rosa Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Monte Rosa Therapeutics Inc shares?
plus_minus_icon
How can I buy Monte Rosa Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Monte Rosa Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Monte Rosa Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Monte Rosa Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Monte Rosa Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Monte Rosa Therapeutics Inc?
plus_minus_icon
What percentage is Monte Rosa Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Monte Rosa Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$7.71
$0.07
(0.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00